Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-26
2007-06-26
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211040, C514S211110
Reexamination Certificate
active
11042752
ABSTRACT:
The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK1) receptor. In particular, these compounds are useful in the treatment of diseases in which Substance P is involved such as, for example, major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, and urticaria.
REFERENCES:
patent: 680962 (1995-11-01), None
patent: WO 95/16682 (1995-06-01), None
patent: WO 96/28158 (1996-09-01), None
patent: WO 00/02859 (2000-01-01), None
patent: WO 00/20003 (2000-04-01), None
patent: WO 00/20389 (2000-04-01), None
patent: WO 00/34243 (2000-06-01), None
patent: WO 00/64423 (2000-11-01), None
Aharony et al., “Isolation and pharmacological characterization of a hamster urinary bladder neurokinin A receptor cDNA,”Molecular Pharmacology(1994) 45:9-19.
Bajusz et al., “A superactive antinociceptive pentapeptide, (D-Met2, Pro5)-enkephalinamide,”Fed Eur Biochem Soc(1977) 76(1):91.
Beaujouan et al., “Quantitative autoradiographic analysis of the distribution of binding sites for [125I]Bolton Hunter derivatives of eledoisin and substance P in the rat brain,”Neurosci. (1986) 18(4):857-875.
Buckner et al., “Differential blockade by tachykinin NK1 and NK2 receptor antagonists of bronchoconstriction induced by direct-acting agonists and the indirect-acting mimetics capsaicin, serotonin and 2-methyl-serotonin in the anesthetized guinea pig,”J Pharm Exp Ther(1993) 267(3):1168-1175.
Culman et al., “Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress,”J Pharmacol Exp Ther(1997) 280(1):238-246.
File “Recent developments in anxiety, stress, and depression,”Pharmacol, Biochem&Behavior(1996) 54(1):3-12.
File “Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test,”Pharmacol, Biochem&Behavior(1997) 58(3):747-752.
Forchetti et al., “Serotonin and gamma-aminobutyric acid turnover after injection into the median raphe of substance P and D-ala-met-enkephalin amide,”J. Neurochem(1982) 38:1336-1341.
Graeff et al., “Role of 5-HT in stress, anxiety, and depression,”Pharmacol, Biochem&Behavior(1996) 54(1):129-141.
Hopkins et al., “Isolation and characterisation of the human lung NK-1 receptor cDNA. Biochem Biophys Res Commun,”Biochem Biophys Res Comm(1991) 180(2):1110-1117.
Ku et al., “Role of corticotropin-releasing factor and substance P in pressor responses of nuclei controlling emotion and stress,”Peptides(1998) 19(4):677-682.
Iversen “Central Actions of Substance P and Related Tachykinins,”Psychopharmacology(1989) 3(1):1-6.
Oki “The Chemistry of Rotational Isomers,”Springer Verlag, NY(1993).
Steinberg et al., “Expression and presence of septal neurokinin-2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat,”Eur J Neurosci(1998) 10(7):2337-2345.
Stratton et al., “Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box,”Eur Pharmacol(1993) 250(3):R11-R12.
Teixeira et al., “Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice,”Eur J Pharmacol(1996) 311(1):7-14.
Vassout et al., “CGP 49823, a novel NK1receptor antagonist: Behavioural effects,”Neuropeptides(1994) 26(S1):38.
Walsh et al., “The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety,”Psychopharmacolo(1995) 121:186-191.
Wood “A direct conversion of esters to nitriles,”Tetrahedron Lett(1979) 20(51):4907.
Aslanian et al., “Section II. Cardiovascular and Pulmonary Diseases,”Annual Reports in Medicinal Chemistry(2001) 36:31-51.
Swain et al., Section I-Central Nervous System Disease, Ann Reports Med. Chem (1999) 34:52-60.
Baroncelli et al., “Evidence of Increased Levels of Substance P in Obese Children,” Functional Neurology (1989) 4:183-184. (Abstract Only).
Cao et al., “Use of NK(1) knockout mice to analyze substance P-induced edema formation,” American Journal of Physiology (1999) 277(2 Pt. 2) R476-R481.
De Felipe et al., “Altered nociception, analgesia and aggression in mice lacking the receptor for substance P,” Nature (1998) 392(6674):394-397.
Garret et al., “Pharmacological properties of a potent and selective nonpeptide substance P antagonist,” Proc. Natl. Acad. Sci. USA (1991) 88(22):10208-10212.
Hanf et al., “Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis,” Inflamm. Res. (2000) 49(10):520-523.
Holzer et al., “Effect of neuropeptides on the efficiency of the peristaltic reflex,” Naunyn-Schmiedeberg's Arch. Pharmacol. (1979) 307(3):257-264.
Joos et al., “Tachykinin receptor antagonists: potential in airways diseases,” Current Opinion in Pharmacology (2001) 1(3):235-241.
Krier et al., “Effect of substance P on colonic mechanoreceptors, motility, and sympathetic neurons,” American Journal of Physiology (1982) 243(4):G259-G267.
Nakano et al., “Platelet substance P and 5-hydroxytryptamine in migraine and tension-type headache,” Headache (1993) 33(10):528-532.
Toth-Kasa et al., “Involvement of sensory nerve endings in cold and heat urticaria,” The Journal of Investigative Dermatology (1983) 80(1):34-36.
Albert Jeffrey Scott
Bernstein Peter
Ohnmacht, Jr. Cyrus
Russell Keith
Shenvi Ashokkumar Bhikkappa
Astrazeneca AB
Cochran Karen
Kifle Bruck
Pepper Hamilton LLP
LandOfFree
Neurokinin antagonists for use as medicaments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurokinin antagonists for use as medicaments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurokinin antagonists for use as medicaments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3875971